Grifols, the Spain-based life sciences firm that wants to buy Triangle-based Talecris (Nasdaq: TLCR), says it expects a decision about the deal to be made by U.S. regulators by March 6.

Talecris recently rescheduled a shareholder meeting to Feb. 14 from January to vote on the merger.

According to Reuters news service, Grifols issued a statement in which the company said it expects a “resolution” of the deal by that day “unless a favorable resolution in reached beforehand.”

Reuters noted that Grifols’ comment indicates the company is still talking to the Federal Trade Commission about the deal.

Grifols and Talacris announced the $4 billion last year. In January, Grifols said it had secured the necessary financing for the deal.

Read the Reuters report here.

Last week, Reuters also provided an in-depth analysis of the Grifols-Talecris deal and whether it would be approved. Read the details here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.